Arvinas, Inc. (ARVN)
Fuera de horario:
Arvinas, Inc.
5 Science Park
395 Winchester Avenue
New Haven, CT 06511
United States
203 535 1456
https://www.arvinas.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 445
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. John G. Houston Ph.D. | Chairperson, CEO & President | 1.14M | N/D | 1960 |
| Dr. Ian Taylor Ph.D. | Chief Scientific Officer | 732.26k | N/D | 1963 |
| Ms. Angela M. Cacace Ph.D. | Senior Vice President of Neuroscience & Platform Biology | N/D | N/D | 1968 |
| Mr. John P. Northcott | Chief Commercial Officer | N/D | N/D | 1978 |
| Ms. Lisa Sinclair | Senior Vice President of Corporate Operations | N/D | N/D | N/D |
| Mr. Paul McInulty | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
| Mr. Alexander A. Santini | Senior Vice President of Global & U.S. Market Access | N/D | N/D | 1959 |
| Ms. Kelly Page | Senior VP & Global Head of Oncology Strategy and Program Leadership | N/D | N/D | N/D |
| Dr. Eric Masson Pharm.D. | Senior Vice President of Early Clinical Development | N/D | N/D | N/D |
| Dr. Janet Wang Ph.D. | VP & Head of Translational Sciences, Oncology | N/D | N/D | N/D |
Descripción
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Gestión corporativa
La calificación ISS Governance QuickScore de Arvinas, Inc. a partir del 29 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 3; Junta: 8; Derechos del accionista: 8; Compensación: 8.
